Clinical Trial Update: PDR001 Combination Therapy for Radioiodine-Refractory Thyroid Cancer [Phase 2]

View source ↗

Summary

Phase 2 clinical trial evaluating PDR001 in combination therapy for radioiodine-refractory thyroid cancer is active but not recruiting.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Follicular Thyroid Cancer
• Hurthle Cell Thyroid Tumor
• Papillary Thyroid Cancer
• Poorly Differentiated Thyroid Carcinoma
• Thyroid Cancer

Drugs mentioned

• PDR001

Snippet

Sponsor: Memorial Sloan Kettering Cancer Center | Conditions: Thyroid Cancer, Thyroid Cancer, Follicular | Phase 2 | Status: ACTIVE_NOT_RECRUITING